Evolving Barriers to Clinical Trial Enrollment and Clinical Care in Neuro-oncology in the Face of COVID-19

Nikhil Grandhi, Alice Y. Zhou, Margaret O. Johnson, Omar H. Butt

Research output: Contribution to journalArticlepeer-review


The lack of treatments with durable response in neuro-oncology highlights the critical need for clinical trials to advance patient care. The intersection of relatively low incidence, evolving classification schema, and entrenched community, healthcare provider, and organizational factors have been historic challenges against successful trial enrollment and implementation. The additional need for multidisciplinary, often tertiary-level care, further magnifies latent national and international health inequities with rural and under-served populations. The COVID-19 pandemic both unveiled fundamental weaknesses in historical approaches and prompted the necessity of new approaches and systems for conducting clinical trials. Here, we provide an overview of traditional barriers to clinical trial enrollment in neuro-oncology, the effect of COVID-19 on these barriers, and the discovery of additional systemic weaknesses. Finally, we discuss future directions by reflecting on lessons learned with strategies to broaden access of care and streamline clinical trial integration into clinical practice.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalSeminars in Neurology
Issue number1
StatePublished - Jan 17 2024


  • COVID-19
  • barriers
  • clinical trials
  • inequities
  • neuro-oncology


Dive into the research topics of 'Evolving Barriers to Clinical Trial Enrollment and Clinical Care in Neuro-oncology in the Face of COVID-19'. Together they form a unique fingerprint.

Cite this